Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia

Ulrik Pedersen-Bjergaard; Peter Lommer Kristensen; Kirsten Nørgaard; Hans Perrild; Tonny Jensen; Birger Thorsteinsson; Annie Nikolajsen; Lise Tarnow

doi:10.1080/03007995.2016.1205006

Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia

Ulrik Pedersen-Bjergaard^*, Peter Lommer Kristensen, Kirsten Nørgaard, Hans Perrild, Tonny Jensen, Birger Thorsteinsson, Annie Nikolajsen, Lise Tarnow

^*Corresponding author for this work

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

Objective: Based on the data of the HypoAna trial (ClinicalTrials.gov NCT00346996), a short-term cost–effectiveness analysis was conducted comparing an all insulin analogue regimen with an all human insulin regimen in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Methods: Clinical data from the HypoAna trial and Danish cost data related to the treatment of severe hypoglycemia were used to populate a 1-year cost–effectiveness analysis. Hypoglycemia quality-of-life data were based on previously published utility values, used to calculate the quality-adjusted life-years (QALYs) gained. Sensitivity analyses were conducted to test the robustness of the analysis. The main outcome measure was the incremental cost–effectiveness ratio (ICER). Results: The insulin analogue regimen was associated with greater total costs compared with the human insulin regimen (20,418 DKK [1972 GBP] vs. 18,558 DKK [1793 GBP], respectively), primarily driven by the difference in insulin costs. Total costs for corrective actions for hypoglycemic events, however, were lower in the insulin analogue group (927 DKK [89 GBP]) compared with the human insulin group (1311 DKK [127 GBP]), primarily due to a lower event rate. QALYs were higher with insulin analogues vs. human insulin (difference 0.0672). The resulting ICER was 27,685 DKK (2674 GBP) per QALY gained, which is well below the generally accepted cost–effectiveness threshold. Conclusions: The analysis shows that treating people with type 1 diabetes who are prone to recurrent severe hypoglycemia with an insulin analogue regimen is cost-effective compared with a human insulin regimen.

Original language	English
Journal	Current Medical Research and Opinion
Volume	32
Issue number	10
Pages (from-to)	1719-1725
Number of pages	7
ISSN	0300-7995
DOIs	https://doi.org/10.1080/03007995.2016.1205006
Publication status	Published - 2016

Keywords

Cost analysis
Diabetes complications
Hypoglycemia
Insulin
Type 1 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/03007995.2016.1205006

03007995.2016.1205006?needAccess=trueFinal published version, 959 KB

Cite this

Pedersen-Bjergaard, U., Kristensen, P. L., Nørgaard, K., Perrild, H., Jensen, T., Thorsteinsson, B., Nikolajsen, A., & Tarnow, L. (2016). Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Current Medical Research and Opinion, 32(10), 1719-1725. https://doi.org/10.1080/03007995.2016.1205006

Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. / Pedersen-Bjergaard, Ulrik; Kristensen, Peter Lommer; Nørgaard, Kirsten et al.

In: Current Medical Research and Opinion, Vol. 32, No. 10, 2016, p. 1719-1725.

Research output: Contribution to journal › Journal article › Research › peer-review

Pedersen-Bjergaard, U, Kristensen, PL, Nørgaard, K , Perrild, H, Jensen, T, Thorsteinsson, B, Nikolajsen, A & Tarnow, L 2016, 'Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia', Current Medical Research and Opinion, vol. 32, no. 10, pp. 1719-1725. https://doi.org/10.1080/03007995.2016.1205006

@article{afe84b5c8b094c449b43111507404988,

title = "Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia",

abstract = "Objective: Based on the data of the HypoAna trial (ClinicalTrials.gov NCT00346996), a short-term cost–effectiveness analysis was conducted comparing an all insulin analogue regimen with an all human insulin regimen in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Methods: Clinical data from the HypoAna trial and Danish cost data related to the treatment of severe hypoglycemia were used to populate a 1-year cost–effectiveness analysis. Hypoglycemia quality-of-life data were based on previously published utility values, used to calculate the quality-adjusted life-years (QALYs) gained. Sensitivity analyses were conducted to test the robustness of the analysis. The main outcome measure was the incremental cost–effectiveness ratio (ICER). Results: The insulin analogue regimen was associated with greater total costs compared with the human insulin regimen (20,418 DKK [1972 GBP] vs. 18,558 DKK [1793 GBP], respectively), primarily driven by the difference in insulin costs. Total costs for corrective actions for hypoglycemic events, however, were lower in the insulin analogue group (927 DKK [89 GBP]) compared with the human insulin group (1311 DKK [127 GBP]), primarily due to a lower event rate. QALYs were higher with insulin analogues vs. human insulin (difference 0.0672). The resulting ICER was 27,685 DKK (2674 GBP) per QALY gained, which is well below the generally accepted cost–effectiveness threshold. Conclusions: The analysis shows that treating people with type 1 diabetes who are prone to recurrent severe hypoglycemia with an insulin analogue regimen is cost-effective compared with a human insulin regimen.",

keywords = "Cost analysis, Diabetes complications, Hypoglycemia, Insulin, Type 1 diabetes mellitus",

author = "Ulrik Pedersen-Bjergaard and Kristensen, {Peter Lommer} and Kirsten N{\o}rgaard and Hans Perrild and Tonny Jensen and Birger Thorsteinsson and Annie Nikolajsen and Lise Tarnow",

year = "2016",

doi = "10.1080/03007995.2016.1205006",

language = "English",

volume = "32",

pages = "1719--1725",

journal = "Current Medical Research and Opinion, Supplement",

issn = "0141-9951",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia

AU - Pedersen-Bjergaard, Ulrik

AU - Kristensen, Peter Lommer

AU - Nørgaard, Kirsten

AU - Perrild, Hans

AU - Jensen, Tonny

AU - Thorsteinsson, Birger

AU - Nikolajsen, Annie

AU - Tarnow, Lise

PY - 2016

Y1 - 2016

N2 - Objective: Based on the data of the HypoAna trial (ClinicalTrials.gov NCT00346996), a short-term cost–effectiveness analysis was conducted comparing an all insulin analogue regimen with an all human insulin regimen in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Methods: Clinical data from the HypoAna trial and Danish cost data related to the treatment of severe hypoglycemia were used to populate a 1-year cost–effectiveness analysis. Hypoglycemia quality-of-life data were based on previously published utility values, used to calculate the quality-adjusted life-years (QALYs) gained. Sensitivity analyses were conducted to test the robustness of the analysis. The main outcome measure was the incremental cost–effectiveness ratio (ICER). Results: The insulin analogue regimen was associated with greater total costs compared with the human insulin regimen (20,418 DKK [1972 GBP] vs. 18,558 DKK [1793 GBP], respectively), primarily driven by the difference in insulin costs. Total costs for corrective actions for hypoglycemic events, however, were lower in the insulin analogue group (927 DKK [89 GBP]) compared with the human insulin group (1311 DKK [127 GBP]), primarily due to a lower event rate. QALYs were higher with insulin analogues vs. human insulin (difference 0.0672). The resulting ICER was 27,685 DKK (2674 GBP) per QALY gained, which is well below the generally accepted cost–effectiveness threshold. Conclusions: The analysis shows that treating people with type 1 diabetes who are prone to recurrent severe hypoglycemia with an insulin analogue regimen is cost-effective compared with a human insulin regimen.

AB - Objective: Based on the data of the HypoAna trial (ClinicalTrials.gov NCT00346996), a short-term cost–effectiveness analysis was conducted comparing an all insulin analogue regimen with an all human insulin regimen in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Methods: Clinical data from the HypoAna trial and Danish cost data related to the treatment of severe hypoglycemia were used to populate a 1-year cost–effectiveness analysis. Hypoglycemia quality-of-life data were based on previously published utility values, used to calculate the quality-adjusted life-years (QALYs) gained. Sensitivity analyses were conducted to test the robustness of the analysis. The main outcome measure was the incremental cost–effectiveness ratio (ICER). Results: The insulin analogue regimen was associated with greater total costs compared with the human insulin regimen (20,418 DKK [1972 GBP] vs. 18,558 DKK [1793 GBP], respectively), primarily driven by the difference in insulin costs. Total costs for corrective actions for hypoglycemic events, however, were lower in the insulin analogue group (927 DKK [89 GBP]) compared with the human insulin group (1311 DKK [127 GBP]), primarily due to a lower event rate. QALYs were higher with insulin analogues vs. human insulin (difference 0.0672). The resulting ICER was 27,685 DKK (2674 GBP) per QALY gained, which is well below the generally accepted cost–effectiveness threshold. Conclusions: The analysis shows that treating people with type 1 diabetes who are prone to recurrent severe hypoglycemia with an insulin analogue regimen is cost-effective compared with a human insulin regimen.

KW - Cost analysis

KW - Diabetes complications

KW - Hypoglycemia

KW - Insulin

KW - Type 1 diabetes mellitus

U2 - 10.1080/03007995.2016.1205006

DO - 10.1080/03007995.2016.1205006

M3 - Journal article

C2 - 27326862

AN - SCOPUS:84978700559

SN - 0141-9951

VL - 32

SP - 1719

EP - 1725

JO - Current Medical Research and Opinion, Supplement

JF - Current Medical Research and Opinion, Supplement

IS - 10

ER -

Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this